The Memo: Vascudyne Engineering Regenerative Tissue for Cardiovascular Repair

Under the direction of CEO Zeeshan Syedain, PhD, Vascudyne is developing off-the-shelf, regenerative tissue implants designed to integrate with the patient’s body and remodel into living tissue. The St. Paul, Minnesota-based company is advancing engineered blood vessels and heart valves, with its lead clinical program focused on coronary artery bypass grafting (CABG) and additional work targeting congenital heart defects. Vascudyne’s approach centers on a human cell-derived biological matrix rather than synthetic material, with the goal of giving surgeons a readily available biological implant that can become populated by the patient’s own cells over time.

Origin Story

Vascudyne’s technology originated in Professor Robert Tranquillo’s lab at the University of Minnesota, where Dr. Syedain earned his PhD. As a co-inventor of the company’s core technology, his research centered on a fundamental question: could a bioengineered blood vessel or heart valve be grown in the lab and ultimately be integrated with a patient's own tissue?

For Dr. Syedain, the impetus to translate that work into a company came from seeing a disconnect between what researchers were demonstrating in the laboratory and what surgeons could offer their patients.

“What got me excited wasn’t the elegance of the science; it was watching the gap between what we could do in the lab and what surgeons could actually offer patients.”

The team had generated preclinical data showing engineered vessels and heart valves remodeling into functional, growing tissue. At the same time, cardiac surgeons still routinely relied on harvesting a patient’s own vessels for bypass procedures. Vascudyne was formed to close that gap, licensing the platform from the University of Minnesota and building the manufacturing, quality, and clinical infrastructure required to move it toward patients.

Dr. Syedain has been closely involved throughout that translation. After leading Vascudyne’s technical and translational work since its inception, he became CEO in June 2025.

“That progression as an engineer and scientist to co-inventor to CEO is unusual, but it’s the reason I’m here. I’ve personally been in the room for the process development, the first-in-human implant in Paraguay, the EU trial sites in Poland, and the regulatory conversations.”

For Dr. Syedain, that combination of scientific and translational experience is particularly important as Vascudyne moves further into clinical development. “I understand where the pitfalls are with any advanced technology,” he said, “and I think that’s what a clinical-stage company needs from a CEO right now: someone who can hold the science and the regulatory/commercial path in the same head.”

The Current Landscape

Vascudyne is initially targeting two cardiovascular challenges rooted in a similar unmet need: the lack of an ideal off-the-shelf blood vessel or pediatric heart valve.

In coronary bypass surgery, the internal mammary artery is typically used for the left anterior descending artery, followed by autologous saphenous vein or radial artery for additional targets. Harvesting a saphenous vein creates a second surgical wound with its own potential for infection and healing complications, and vein grafts can fail over time. Some patients also lack adequate conduit because of prior harvest, varicosities, diabetes, or peripheral vascular disease. In those cases, surgeons may be left with incomplete revascularization or a hybrid approach incorporating stents.

Congenital heart disease presents a different problem. A child who needs a right ventricular outflow tract conduit may receive a cryopreserved homograft or bovine jugular vein conduit. These options are fixed in size and subject to degeneration and calcification. Critically, they do not grow with the child, meaning replacement procedures may be necessary throughout childhood and adolescence.

“Each one of these is a compromise,” Dr. Syedain explained. “The autologous options require harvesting tissue from the patient. The synthetic and fixed-tissue options don’t integrate, don’t grow, and degrade over time.”

Vascudyne is pursuing an alternative design around regeneration rather than inert replacement.

“Our mission is straightforward: no patient should have to choose between a piece of their own body being harvested, a plastic tube that will eventually fail, or a valve that has to be replaced every few years. We want a shelf-stable, any-size biological implant that a surgeon can pick up and use.”

Inside the Innovation

Vascudyne engineers human tissue in bioreactors at its GMP manufacturing facility, controlling the dimensions of the tissue for different indications. Its platform can produce, for example, a 4 mm-diameter vessel for coronary bypass or a 20 mm-diameter vessel for a pulmonary valved conduit.

According to the company, its manufacturing process begins with a fibrin scaffold derived from plasma. Human cells are added to the scaffold, where they produce tissue matrix composed of collagen and other extracellular proteins. As the tissue matures in bioreactors, it develops into a native-like architecture. The cells are then removed, leaving an acellular biological matrix that can be prepared for storage and transportation.

The intended distinction comes after implantation. Rather than remaining a permanent foreign material, the engineered matrix is designed to be repopulated and remodeled by the recipient’s own cells.

“Our bioengineered tissue is acellular and non-immunogenic tissue; the patient’s own cells populate the matrix and, over time, it behaves as native tissue.”

Dr. Syedain said Vascudyne has observed host-cell repopulation and remodeling in its preclinical and clinical work.

For coronary bypass, the off-the-shelf approach could eliminate the need to harvest another vessel and provide surgeons with a conduit in the required size at the time of surgery. In congenital heart disease, Vascudyne is pursuing something more difficult: an implant with the potential to remodel into living tissue and grow along with a patient’s body.

As Dr. Syedain put it, “A conduit that remodels into living tissue is a conduit that can grow with the child. That’s the difference between one operation and four.”

The platform’s differentiation also extends to how it is manufactured. Vascudyne operates a more than 10,000-square-foot facility with dual ISO 7 clean rooms under a formal quality management system aligned with ISO 13485 and ISO 14971.

“This is our strength to control manufacturing and our know-how of a complex science,” Dr. Syedain said of manufacturing.

Progress and Milestones

Vascudyne is now a clinical-stage company, with its lead coronary bypass program progressing in Europe while it advances parallel U.S. programs.

Its first-in-human coronary bypass work was conducted in Paraguay, and in 2026, results from a first-in-human coronary artery bypass implant using an engineered acellular conduit were published in JACC: Case Reports. The company has since advanced to a multicenter European CABG trial in Poland under EU MDR. 

The geography is deliberate. Vascudyne is pursuing what Dr. Syedain describes as a dual-track strategy, seeking a CE mark in Europe for its coronary conduit while advancing its U.S. FDA pathway, including work on pediatric devices through a Department of Defense-funded clinical program.

“Europe gave us a faster, well-controlled path to meaningful clinical evidence in coronary bypass,” Dr. Syedain said, “and we now have surgeons across multiple centers with real implant experience.”

Near-term priorities include follow-up in the European CABG trial and moving toward the design of a pivotal trial. In parallel, Vascudyne is advancing its U.S. FDA pathway for adult and pediatric clinical studies and working toward completion of the GLP preclinical package for its valved conduit.

The company and its partners have received more than $10 million in non-dilutive funding from the Department of Defense and National Institutes of Health, including a Congressionally Directed Medical Research Programs-funded pediatric valved conduit program and an NIH Catalyze award supporting CABG regulatory studies. Vascudyne also raised $15 million in new Series B funding in 2026, bringing its total Series A and B financing to $50 million plus.

Vascudyne is now actively raising a Series C to fund Phase II and pivotal trials in the U.S. and Europe for its first indication while supporting clinical studies for its heart valve program. Longer term, the company sees its engineered matrix extending beyond coronary bypass and congenital heart defects into additional applications, including transcatheter valves, as well as wound and soft tissue regeneration.

That progression is also changing the conversations Dr. Syedain wants Vascudyne to have at LSI Europe.

“We’ve spent a long time heads-down on the science and the clinical work. We’re at the point where the conversation shifts from ‘does this work?’ to ‘how do we get this to every surgeon who needs it?’ and that’s a very different set of relationships.”

Vascudyne is coming to Barcelona seeking investors who understand the unmet need in cardiovascular care and conversations with potential strategic partners as it prepares for its next stage of clinical development.

Join Us at LSI Europe ‘26

Dr. Syedain has been selected to present at LSI Europe '26, September 28th–October 1st, in front of hundreds of global medical technology companies. Join us in welcoming him to the event in Barcelona, where he will share the latest updates on Vascudyne’s technology and development.